The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Heidi Wagner Biography and Net Worth

SVP of Alexion Pharmaceuticals

Heidi L. Wagner serves as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., where she is responsible for developing and implementing comprehensive strategies related to health care policy and patient access. Throughout her career, she has held roles responsible for all aspects of government affairs and pricing including overseeing a broad portfolio of legislative and regulatory policy issues at international, national and local levels, and overseeing discussions relating to pricing, reimbursement and patient access, as well as patient advocacy. Previously, Ms. Wagner served as Senior Vice President of Global Government Affairs at Alexion where she successfully led funding negotiations and global payor strategy in support of the company’s rare disease portfolio across its 50-country platform; she also held early leadership roles at Genentech, Inc. and the Healthcare Leadership Council. Ms. Wagner earned a JD at George Mason University School of Law and a BS in Journalism & Mass Communication from the University of Colorado, Boulder.

What is Heidi L. Wagner's net worth?: The estimated net worth of Heidi L. Wagner is at least $8.62 million as of February 8th, 2018. Ms. Wagner owns 47,212 shares of Alexion Pharmaceuticals stock worth more than $8,616,190 as of May 7th. This net worth estimate does not reflect any other assets that Ms. Wagner may own. Learn More about Heidi L. Wagner's net worth.
How do I contact Heidi L. Wagner?: The corporate mailing address for Ms. Wagner and other Alexion Pharmaceuticals executives is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. Alexion Pharmaceuticals can also be reached via phone at 475-230-2596 and via email at [email protected]. Learn More on Heidi L. Wagner's contact information.
Has Heidi L. Wagner been buying or selling shares of Alexion Pharmaceuticals?: Heidi L. Wagner has not been actively trading shares of Alexion Pharmaceuticals during the past quarter. Most recently, Heidi L. Wagner sold 698 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $119.35, for a transaction totalling $83,306.30. Learn More on Heidi L. Wagner's trading history.
Who are Alexion Pharmaceuticals' active insiders?: Alexion Pharmaceuticals' insider roster includes Daniel Bazarko (CAO), Tanisha Carino (CAO), Paul Clancy (CFO), Indrani Franchini (EVP), Ludwig Hantson (CEO), John Orloff (EVP), Vikas Sinha (CFO), and Heidi Wagner (SVP). Learn More on Alexion Pharmaceuticals' active insiders.

Heidi L. Wagner Insider Trading History at Alexion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/28/2018	Sell	698	$119.35	$83,306.30
2/8/2018	Sell	1,774	$116.31	$206,333.94	47,212
2/5/2018	Sell	655	$117.26	$76,805.30	32,635
10/2/2017	Sell	120	$140.00	$16,800.00
3/1/2017	Sell	994	$131.65	$130,860.10	29,646
2/7/2017	Sell	1,932	$125.97	$243,374.04	30,241
11/14/2016	Sell	59	$115.10	$6,790.90	31,936
10/3/2016	Sell	120	$122.41	$14,689.20	31,995
8/8/2016	Sell	222	$137.14	$30,445.08	32,115
5/13/2016	Sell	53	$138.65	$7,348.45	32,337
2/8/2016	Sell	2,108	$140.93	$297,080.44	29,937

Heidi L. Wagner Buying and Selling Activity at Alexion Pharmaceuticals

Alexion Pharmaceuticals Company Overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $182.50

$182.50

50 Day Range

MA: $182.82

$179.45

$186.61

2 Week Range

Now: $182.50

$99.91

$187.45

Volume

10 shs

Average Volume

3,309,941 shs

Market Capitalization

$40.34 billion

P/E Ratio

59.64

Dividend Yield

N/A

Beta

1.25